Implementing improved analytical methods to support vaccine quality - Part 1 (from Sep 15)
Information
Watch on demand on Sep 24, or join LIVE on Sep 15 by registering here:
www.attendee.gotowebinar.com/register/6511056480271037965
Sep 15: PART ONE: approx. 10AM EST – 12PM EST
Workshop opening remarks
Dr Earl Zablackis, Director-Principle Scientist, Sanofi Pasteur
Molecular size, from distribution coefficient to multiple measured characteristics using light scattering-not as easy as you would think
Dr Earl Zablackis, Director-Principle Scientist, Sanofi Pasteur
Use of NMR assays for characterization of polysaccharide-based vaccines
Francesco Berti, Scientific Director – Analytical/Technical R&D, GSK Vaccines
Substituting in vitro for in vivo vaccine potency and safety assays: science versus the fear factor: Dr Dean Smith, Section Head & Senior Scientific Evaluator of Vaccines, Health Canada
A regulatory perspective on NGS for adventitious virus detection in biologics
Dr Arifa Khan, Principal Investigator/Supervisory Microbiologist in the Division of Viral Products, CBER, FDA
Panel with all speakers
Moderated by Dr Dirk Redlich, VP, Head CMC Development and Clinical Trial Material Manufacturing, Janssen
